Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes: A RELAX Trial Ancillary Study

The RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction) study was a multicenter, randomized trial of sildenafil versus placebo in heart failure with preserved ejection fraction (HFpEF) with rigorous entry criteria...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2014-08, Vol.64 (6), p.541-549
Hauptverfasser:	LINDMAN, Brian R, DAVILA-ROMAN, Victor G, REDFIELD, Margaret M, MANN, Douglas L, McNULTY, Steven, SEMIGRAN, Marc J, LEWIS, Gregory D, DE LAS FUENTES, Lisa, JOSEPH, Susan M, VADER, Justin, HERNANDEZ, Adrian F
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biological and medical sciences Cardiology. Vascular system Cohort Studies Diabetes Mellitus - diagnosis Diabetes Mellitus - drug therapy Diabetes Mellitus - epidemiology Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Heart Heart Failure - diagnosis Heart Failure - drug therapy Heart Failure - epidemiology Humans Male Medical sciences Middle Aged Phenotype Phosphodiesterase 5 Inhibitors - pharmacology Phosphodiesterase 5 Inhibitors - therapeutic use Piperazines - pharmacology Piperazines - therapeutic use Prospective Studies Purines - pharmacology Purines - therapeutic use Sildenafil Citrate Stroke Volume - drug effects Stroke Volume - physiology Sulfones - pharmacology Sulfones - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!